statistiche ricercatore

Continente	#
NA - Nord America	436
AS - Asia	337
EU - Europa	307
SA - Sud America	72
AF - Africa	11
Continente sconosciuto - Info sul continente non disponibili	3
OC - Oceania	2
Totale	1.168

Nazione	#
US - Stati Uniti d'America	423
SG - Singapore	157
CN - Cina	78
BR - Brasile	63
SE - Svezia	62
DE - Germania	56
FR - Francia	54
IT - Italia	39
PL - Polonia	36
VN - Vietnam	35
IN - India	19
IE - Irlanda	13
GB - Regno Unito	11
ID - Indonesia	11
FI - Finlandia	9
CA - Canada	8
CI - Costa d'Avorio	8
HK - Hong Kong	7
JP - Giappone	7
UA - Ucraina	7
PK - Pakistan	5
RU - Federazione Russa	5
AT - Austria	4
BD - Bangladesh	4
MX - Messico	4
AR - Argentina	3
AU - Australia	2
ES - Italia	2
IQ - Iraq	2
IR - Iran	2
PE - Perù	2
TR - Turchia	2
VE - Venezuela	2
A2 - ???statistics.table.value.countryCode.A2???	1
AE - Emirati Arabi Uniti	1
BE - Belgio	1
CH - Svizzera	1
CL - Cile	1
CO - Colombia	1
DZ - Algeria	1
EE - Estonia	1
EU - Europa	1
GH - Ghana	1
HU - Ungheria	1
IL - Israele	1
KE - Kenya	1
KG - Kirghizistan	1
KR - Corea	1
KZ - Kazakistan	1
LT - Lituania	1
NL - Olanda	1
NO - Norvegia	1
PT - Portogallo	1
RO - Romania	1
SA - Arabia Saudita	1
SY - Repubblica araba siriana	1
TT - Trinidad e Tobago	1
UZ - Uzbekistan	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.168

Nome	#
A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy.	206
High-dose atorvastatin reduces oxidative stress of ischemia/reperfusion injury after isogeneic kidney transplantation in rats: in vivo, preclinical, case–control, open-label study	139
Heparanase: A Potential New Factor Involved in the Renal Epithelial Mesenchymal Transition (EMT) Induced by Ischemia/Reperfusion (I/R) Injury	135
Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura	133
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies	131
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies	119
Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report	117
SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis	101
Heparanase regulates the M1 polarization of renal macrophages and their crosstalk with renal epithelial tubular cells after ischemia/reperfusion injury	99
Totale	1.180

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	7	0	0	0	0	0	0	0	0	0	1	3	3
2021/2022	70	7	2	1	1	6	2	0	13	4	4	16	14
2022/2023	206	26	25	12	34	10	25	17	19	32	0	5	1
2023/2024	64	4	16	1	8	0	6	4	1	0	2	12	10
2024/2025	226	2	6	42	9	13	12	4	12	15	16	49	46
2025/2026	447	73	11	32	66	95	28	74	16	28	24	0	0
Totale													1.180

IRIS UniCatt